Long-Term Outcomes of Exercise Therapy Versus Revascularization in Patients With Intermittent Claudication.
Journal
Annals of surgery
ISSN: 1528-1140
Titre abrégé: Ann Surg
Pays: United States
ID NLM: 0372354
Informations de publication
Date de publication:
01 08 2023
01 08 2023
Historique:
medline:
12
7
2023
pubmed:
3
2
2023
entrez:
2
2
2023
Statut:
ppublish
Résumé
The aim was to analyze the risk of progression to chronic limb-threatening ischemia (CLTI), amputation and subsequent interventions after revascularization versus noninvasive therapy in patients with intermittent claudication (IC). Conflicting evidence exists regarding adverse limb outcomes after each treatment strategy. Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. MEDLINE, Web of Science, and Google Scholar were searched aided by a health sciences librarian through August 16, 2022. Randomized control trials (RCTs) comparing invasive (endovascular or surgical revascularization) and noninvasive treatment (exercise and/or medical treatment) were included. PROSPERO registration was completed (CRD42022352831). A total of 9 RCTs comprising 1477 patients (invasive, 765 patients; noninvasive, 712 patients) were eligible. During a mean of 3.6-year follow-up, progression to CLTI after invasive [5 (2-8) per 1000 person-years] and noninvasive treatment [6 (3-10) per 1000 person-years] were not statistically different [rate ratio (RR): 0.77; 95% CI, 0.35-1.69; P =0.51, I2 =0%]. Incidence of amputation (RR: 1.69; 95% CI, 0.54-5.26; P =0.36, I2 =0%) and all-cause mortality (hazard ratio: 1.26; 95% CI, 0.91-1.74; P =0.16, I2 =0%) also did not differ between the groups. However, the invasive treatment group underwent significantly more revascularizations (RR: 4.15; 95% CI, 2.80-6.16; P <0.00001, I2 =83%). The results were not changed by fixed effect or random-effects models, nor by sensitivity analysis. Although there is equivalent risk of progression to CLTI, major amputation and all-cause mortality compared with noninvasive treatment, invasive treatment for patients with IC led to significantly more revascularization procedures and should be used selectively in patients with major lifestyle limitation. Guideline recommendation of noninvasive treatment for first-line IC therapy is supported.
Sections du résumé
OBJECTIVE
The aim was to analyze the risk of progression to chronic limb-threatening ischemia (CLTI), amputation and subsequent interventions after revascularization versus noninvasive therapy in patients with intermittent claudication (IC).
BACKGROUND
Conflicting evidence exists regarding adverse limb outcomes after each treatment strategy.
METHODS
Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. MEDLINE, Web of Science, and Google Scholar were searched aided by a health sciences librarian through August 16, 2022. Randomized control trials (RCTs) comparing invasive (endovascular or surgical revascularization) and noninvasive treatment (exercise and/or medical treatment) were included. PROSPERO registration was completed (CRD42022352831).
RESULTS
A total of 9 RCTs comprising 1477 patients (invasive, 765 patients; noninvasive, 712 patients) were eligible. During a mean of 3.6-year follow-up, progression to CLTI after invasive [5 (2-8) per 1000 person-years] and noninvasive treatment [6 (3-10) per 1000 person-years] were not statistically different [rate ratio (RR): 0.77; 95% CI, 0.35-1.69; P =0.51, I2 =0%]. Incidence of amputation (RR: 1.69; 95% CI, 0.54-5.26; P =0.36, I2 =0%) and all-cause mortality (hazard ratio: 1.26; 95% CI, 0.91-1.74; P =0.16, I2 =0%) also did not differ between the groups. However, the invasive treatment group underwent significantly more revascularizations (RR: 4.15; 95% CI, 2.80-6.16; P <0.00001, I2 =83%). The results were not changed by fixed effect or random-effects models, nor by sensitivity analysis.
CONCLUSIONS
Although there is equivalent risk of progression to CLTI, major amputation and all-cause mortality compared with noninvasive treatment, invasive treatment for patients with IC led to significantly more revascularization procedures and should be used selectively in patients with major lifestyle limitation. Guideline recommendation of noninvasive treatment for first-line IC therapy is supported.
Identifiants
pubmed: 36728522
doi: 10.1097/SLA.0000000000005793
pii: 00000658-202308000-00005
doi:
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
172-178Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Fowkes FGR, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet Lond Engl. 2013;382:1329–1340.
Kannel WB, Skinner JJ, Schwartz MJ, et al. Intermittent claudication. Incidence in the Framingham Study. Circulation. 1970;41:875–883.
Dormandy J, Heeck L, Vig S. The natural history of claudication: risk to life and limb. Semin Vasc Surg. 1999;12:123–137.
Kumakura H, Kanai H, Hojo Y, et al. Long-term survival and fate of the leg in de novo intermittent claudication. Eur Heart J Qual Care Clin Outcomes. 2017;3:208–215.
Rantner B, Kollerits B, Pohlhammer J, et al. The fate of patients with intermittent claudication in the 21st century revisited—results from the CAVASIC Study. Sci Rep. 2017;8:45833.
Lane R, Harwood A, Watson L, et al. Exercise for intermittent claudication. Cochrane Database Syst Rev. 2017;12:CD000990.
Fakhry F, Fokkenrood HJ, Spronk S, et al. Endovascular revascularisation versus conservative management for intermittent claudication. Cochrane Database Syst Rev. 2018;3:CD010512.
Thanigaimani S, Phie J, Sharma C, et al. Network meta-analysis comparing the outcomes of treatments for intermittent claudication tested in randomized controlled trials. J Am Heart Assoc. 2021;10:e019672.
Ankle Brachial Index Collaboration, Fowkes FGR, Murray GD, Butcher I, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300:197–208.
Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e726–e779.
Aboyans V, Ricco JB, Bartelink MLEL, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39:763–816.
Madabhushi V, Davenport D, Jones S, et al. Revascularization of intermittent claudicants leads to more chronic limb-threatening ischemia and higher amputation rates. J Vasc Surg. 2021;74:771–779.
Kret MR, Perrone KH, Azarbal AF, et al. Medical comorbidities but not interventions adversely affect survival in patients with intermittent claudication. J Vasc Surg. 2013;58:1540–1546.
Hicks CW, Holscher CM, Wang P, et al. Overuse of early peripheral vascular interventions for claudication. J Vasc Surg. 2020;71:121–130.e1.
Kim TI, Kiwan G, Mohamedali A, et al. Multiple reinterventions for claudication are associated with progression to chronic limb-threatening ischemia. Ann Vasc Surg. 2021;72:166–174.
Woo K, Siracuse JJ, Klingbeil K, et al. Society for vascular surgery appropriate use criteria for management of intermittent claudication. J Vasc Surg. 2022;76:3–22.e1.
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151:W65–W94.
Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence [Internet]. 2022. Accessed September 1, 2022. https://training.cochrane.org/handbook/archive/v6.2/chapter-14 .
Chapter 6: choosing effect measures and computing estimates of effect [Internet]. 2022. Accessed April 15, 2022. https://training.cochrane.org/handbook/archive/v6.1/chapter-06 .
Shirasu T, Kuno T, Yasuhara J, et al. Meta-analysis finds recurrent infection is more common after endovascular than after open repair of infected abdominal aortic aneurysm. J Vasc Surg. 2022;75:348–355.e10.
Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634.
Greenhalgh RM, Belch JJF, Brown LC, et al. The adjuvant benefit of angioplasty in patients with mild to moderate intermittent claudication (MIMIC) managed by supervised exercise, smoking cessation advice and best medical therapy: results from two randomised trials for stenotic femoropopliteal and aortoiliac arterial disease. Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg. 2008;36:680–688.
Nordanstig J, Gelin J, Hensäter M, et al. Walking performance and health-related quality of life after surgical or endovascular invasive versus non-invasive treatment for intermittent claudication—a prospective randomised trial. Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg. 2011;42:220–227.
Fakhry F, Rouwet EV, den Hoed PT, et al. Long-term clinical effectiveness of supervised exercise therapy versus endovascular revascularization for intermittent claudication from a randomized clinical trial. Br J Surg. 2013;100:1164–1171.
Murphy TP, Cutlip DE, Regensteiner JG, et al. Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: the CLEVER study. J Am Coll Cardiol. 2015;65:999–1009.
Mazari FAK, Khan JA, Samuel N, et al. Long-term outcomes of a randomized clinical trial of supervised exercise, percutaneous transluminal angioplasty or combined treatment for patients with intermittent claudication due to femoropopliteal disease. Br J Surg. 2017;104:76–83.
Lindgren HIV, Qvarfordt P, Bergman S, et al. Swedish Endovascular Claudication Stenting Trialists. Primary Ssenting of the superficial femoral artery in patients with intermittent claudication has durable effects on health-related quality of life at 24 months: results of a randomized controlled trial. Cardiovasc Intervent Radiol. 2018;41:872–881.
Djerf H, Millinger J, Falkenberg M, et al. Absence of long-term benefit of revascularization in patients with intermittent claudication: five-year results from the IRONIC randomized controlled trial. Circ Cardiovasc Interv. 2020;13:e008450.
Klaphake S, Fakhry F, Rouwet EV, et al. Long-term follow-up of a randomized clinical trial comparing endovascular revascularization plus supervised exercise with supervised exercise only for intermittent claudication. Ann Surg. 2022;276:e1035–e1043.
Koelemay MJW, van Reijen NS, van Dieren S, et al. Editor’s choice - randomised clinical trial of supervised exercise therapy vs. endovascular revascularisation for intermittent claudication caused by iliac artery obstruction: the SUPER study. Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg. 2022;63:421–429.
Chapter 13: Assessing risk of bias due to missing results in a synthesis [Internet]. 2022. Accessed November 28, 2022. https://training.cochrane.org/handbook/current/chapter-13 .
Mizzi A, Cassar K, Bowen C, et al. The progression rate of peripheral arterial disease in patients with intermittent claudication: a systematic review. J Foot Ankle Res. 2019;12:40.
Naschitz JE, Ambrosio DA, Chang JB. Intermittent claudication: predictors and outcome. Angiology. 1988;39(1 Pt 1):16–22.
Djerf H, Hellman J, Baubeta Fridh E, et al. Low risk of procedure related major amputation following revascularisation for intermittent claudication: a population based study. Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg. 2020;59:817–822.
Jansen SCP, van Nistelrooij LPJ, Scheltinga MRM, et al. Successful implementation of the exercise first approach for intermittent claudication in the Netherlands is associated with few lower limb revascularisations. Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg. 2020;60:881–887.
Anderson L, Thompson DR, Oldridge N, et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 2016;2016:CD001800.
Stewart RAH, Held C, Hadziosmanovic N, et al. Physical activity and mortality in patients with stable coronary heart disease. J Am Coll Cardiol. 2017;70:1689–1700.
Katsanos K, Spiliopoulos S, Kitrou P, et al. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7:e011245.
Fakhry F, van de Luijtgaarden KM, Bax L, et al. Supervised walking therapy in patients with intermittent claudication. J Vasc Surg. 2012;56:1132–1142.
Divakaran S, Carroll BJ, Chen S, et al. Supervised exercise therapy for symptomatic peripheral artery disease among Medicare beneficiaries between 2017 and 2018: participation rates and outcomes. Circ Cardiovasc Qual Outcomes. 2021;14:e007953.
Bearne LM, Volkmer B, Peacock J, et al. Effect of a home-based, walking exercise behavior change intervention vs usual care on walking in adults with peripheral artery disease: the MOSAIC randomized clinical trial. JAMA. 2022;327:1344–1355.
McDermott MM, Spring B, Tian L, et al. Effect of low-intensity vs high-intensity home-based walking exercise on walk distance in patients with peripheral artery disease: the LITE randomized clinical trial. JAMA. 2021;325:1266–1276.
Waddell A, Seed S, Broom DR, et al. Safety of home-based exercise for people with intermittent claudication: a systematic review. Vasc Med. 2022;27:186–192.